Abstract
In summary, it is clear that in vitro susceptibility testing can predict outcome in selected clinical situations. The clearest data are from the fluconazole-treated AIDS patients with oropharyngeal candidiasis. In this setting, the homogeneity of the underlying immune defect, combined with the ease of identification and monitoring of the infection, creates a near-perfect test situation. In more complex scenarios, such as the heterogeneous population of patients enrolled in a recent study of candidemia, no such clear-cut correlation was present. The importance of host factors in the correlation of the MIC with outcome cannot be overemphasized. Examples of these parameters include patient status (underlying disease, the presence of intravascular catheters, and CD4+ T-cell number), drug pharmacokinetics (absorption and distribution), patient compliance, and drug-drug interactions. Identification of relevant factors can substantially improve the degree of the MIC-outcome correlation and thus improve the clinical utility of in vitro testing. An important feature in this entire process is the role of standardized susceptibility testing procedures. While not without flaws, the proposed NCCLS reference method has been invaluable in allowing multiple investigators to contribute data that can be used to clarify the correlation between the fluconazole MIC and outcome. While the development of simplified second-generation methods is eagerly anticipated, the role of the reference method as a common touchstone is critical. Only by use of either the reference method itself or methods with a known relationship to the reference method can this broad collaborative process really proceed. Current work is focusing on defining interpretive breakpoints for fluconazole and Candida species, refinement of the in vitro procedures used to measure susceptibility to amphotericin B, ketoconazole, and itraconazole, and the acquisition of a broad base of data on the relationship between the MIC and outcome for these three drugs. Although considerable work remains to be done, the available data suggest that solutions to each of these problems are possible and that routine susceptibility testing of fungi will become meaningful for clinical decision making in the foreseeable future.
Full Text
The Full Text of this article is available as a PDF (210.0 KB).
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Anaissie E. J., Bodey G. P., Rinaldi M. G. Emerging fungal pathogens. Eur J Clin Microbiol Infect Dis. 1989 Apr;8(4):323–330. doi: 10.1007/BF01963467. [DOI] [PubMed] [Google Scholar]
- Anaissie E. J., Karyotakis N. C., Hachem R., Dignani M. C., Rex J. H., Paetznick V. Correlation between in vitro and in vivo activity of antifungal agents against Candida species. J Infect Dis. 1994 Aug;170(2):384–389. doi: 10.1093/infdis/170.2.384. [DOI] [PubMed] [Google Scholar]
- Baily G. G., Perry F. M., Denning D. W., Mandal B. K. Fluconazole-resistant candidosis in an HIV cohort. AIDS. 1994 Jun;8(6):787–792. doi: 10.1097/00002030-199406000-00010. [DOI] [PubMed] [Google Scholar]
- Banerjee S. N., Emori T. G., Culver D. H., Gaynes R. P., Jarvis W. R., Horan T., Edwards J. R., Tolson J., Henderson T., Martone W. J. Secular trends in nosocomial primary bloodstream infections in the United States, 1980-1989. National Nosocomial Infections Surveillance System. Am J Med. 1991 Sep 16;91(3B):86S–89S. doi: 10.1016/0002-9343(91)90349-3. [DOI] [PubMed] [Google Scholar]
- Barchiesi F., Colombo A. L., McGough D. A., Fothergill A. W., Rinaldi M. G. In vitro activity of itraconazole against fluconazole-susceptible and -resistant Candida albicans isolates from oral cavities of patients infected with human immunodeficiency virus. Antimicrob Agents Chemother. 1994 Jul;38(7):1530–1533. doi: 10.1128/aac.38.7.1530. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Barchiesi F., Giacometti A., Arzeni D., Branchesi P., Crescenzi G., Ancarani F., Scalise G. Fluconazole and ketoconazole in the treatment of oral and esophageal candidiasis in AIDS patients. J Chemother. 1992 Dec;4(6):381–386. doi: 10.1080/1120009x.1992.11739196. [DOI] [PubMed] [Google Scholar]
- Barchiesi F., Hollis R. J., McGough D. A., Scalise G., Rinaldi M. G., Pfaller M. A. DNA subtypes and fluconazole susceptibilities of Candida albicans isolates from the oral cavities of patients with AIDS. Clin Infect Dis. 1995 Mar;20(3):634–640. doi: 10.1093/clinids/20.3.634. [DOI] [PubMed] [Google Scholar]
- Barchiesi F., Morbiducci V., Ancarani F., Scalise G. Emergence of oropharyngeal candidiasis caused by non-albicans species of Candida in HIV-infected patients. Eur J Epidemiol. 1993 Jul;9(4):455–456. doi: 10.1007/BF00157408. [DOI] [PubMed] [Google Scholar]
- Bart-Delabesse E., Boiron P., Carlotti A., Dupont B. Candida albicans genotyping in studies with patients with AIDS developing resistance to fluconazole. J Clin Microbiol. 1993 Nov;31(11):2933–2937. doi: 10.1128/jcm.31.11.2933-2937.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Bodenhoff J. Resistance studies of Candida albicans, with special reference to two patients subjected to prolonged antimycotic treatment. Odontol Tidskr. 1968 Jun 28;76(3):279–294. [PubMed] [Google Scholar]
- Boken D. J., Swindells S., Rinaldi M. G. Fluconazole-resistant Candida albicans. Clin Infect Dis. 1993 Dec;17(6):1018–1021. doi: 10.1093/clinids/17.6.1018. [DOI] [PubMed] [Google Scholar]
- Calhoun D. L., Roberts G. D., Galgiani J. N., Bennett J. E., Feingold D. S., Jorgensen J., Kobayashi G. S., Shadomy S. Results of a survey of antifungal susceptibility tests in the United States and interlaboratory comparison of broth dilution testing of flucytosine and amphotericin B. J Clin Microbiol. 1986 Feb;23(2):298–301. doi: 10.1128/jcm.23.2.298-301.1986. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Calhoun D. L., Waskin H., White M. P., Bonner J. R., Mulholland J. H., Rumans L. W., Stevens D. A., Galgiani J. N. Treatment of systemic sporotrichosis with ketoconazole. Rev Infect Dis. 1991 Jan-Feb;13(1):47–51. doi: 10.1093/clinids/13.1.47. [DOI] [PubMed] [Google Scholar]
- Cameron M. L., Schell W. A., Bruch S., Bartlett J. A., Waskin H. A., Perfect J. R. Correlation of in vitro fluconazole resistance of Candida isolates in relation to therapy and symptoms of individuals seropositive for human immunodeficiency virus type 1. Antimicrob Agents Chemother. 1993 Nov;37(11):2449–2453. doi: 10.1128/aac.37.11.2449. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Colombo A. L., Barchiesi F., McGough D. A., Rinaldi M. G. Comparison of Etest and National Committee for Clinical Laboratory Standards broth macrodilution method for azole antifungal susceptibility testing. J Clin Microbiol. 1995 Mar;33(3):535–540. doi: 10.1128/jcm.33.3.535-540.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Conly J., Rennie R., Johnson J., Farah S., Hellman L. Disseminated candidiasis due to amphotericin B-resistant Candida albicans. J Infect Dis. 1992 Apr;165(4):761–764. doi: 10.1093/infdis/165.4.761. [DOI] [PubMed] [Google Scholar]
- Dick J. D., Rosengard B. R., Merz W. G., Stuart R. K., Hutchins G. M., Saral R. Fatal disseminated candidiasis due to amphotericin-B-resistant Candida guilliermondii. Ann Intern Med. 1985 Jan;102(1):67–68. doi: 10.7326/0003-4819-102-1-67. [DOI] [PubMed] [Google Scholar]
- Drutz D. J., Lehrer R. I. Development of amphotericin B-resistant Candida tropicalis in a patient with defective leukocyte function. Am J Med Sci. 1978 Jul-Aug;276(1):77–92. [PubMed] [Google Scholar]
- Dupouy-Camet J., Paugam A., Di Donato C., Viguié C., Vicens I., Volle P. J., Tourte-Schaefer C. Résistance au fluconazole en milieu hospitalier. Concordance entre la résistance de Candida albicans in vitro et l'échec thérapeutique. Presse Med. 1991 Sep 14;20(28):1341–1341. [PubMed] [Google Scholar]
- Espinel-Ingroff A., Kerkering T. M., Goldson P. R., Shadomy S. Comparison study of broth macrodilution and microdilution antifungal susceptibility tests. J Clin Microbiol. 1991 Jun;29(6):1089–1094. doi: 10.1128/jcm.29.6.1089-1094.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Espinel-Ingroff A., Kish C. W., Jr, Kerkering T. M., Fromtling R. A., Bartizal K., Galgiani J. N., Villareal K., Pfaller M. A., Gerarden T., Rinaldi M. G. Collaborative comparison of broth macrodilution and microdilution antifungal susceptibility tests. J Clin Microbiol. 1992 Dec;30(12):3138–3145. doi: 10.1128/jcm.30.12.3138-3145.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Fan-Havard P., Capano D., Smith S. M., Mangia A., Eng R. H. Development of resistance in candida isolates from patients receiving prolonged antifungal therapy. Antimicrob Agents Chemother. 1991 Nov;35(11):2302–2305. doi: 10.1128/aac.35.11.2302. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Fox R., Neal K. R., Leen C. L., Ellis M. E., Mandal B. K. Fluconazole resistant candida in AIDS. J Infect. 1991 Mar;22(2):201–204. doi: 10.1016/0163-4453(91)91767-r. [DOI] [PubMed] [Google Scholar]
- Fromtling R. A., Galgiani J. N., Pfaller M. A., Espinel-Ingroff A., Bartizal K. F., Bartlett M. S., Body B. A., Frey C., Hall G., Roberts G. D. Multicenter evaluation of a broth macrodilution antifungal susceptibility test for yeasts. Antimicrob Agents Chemother. 1993 Jan;37(1):39–45. doi: 10.1128/aac.37.1.39. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Galgiani J. N., Reiser J., Brass C., Espinel-Ingroff A., Gordon M. A., Kerkering T. M. Comparison of relative susceptibilities of Candida species to three antifungal agents as determined by unstandardized methods. Antimicrob Agents Chemother. 1987 Sep;31(9):1343–1347. doi: 10.1128/aac.31.9.1343. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Galgiani J. N., Stevens D. A., Graybill J. R., Dismukes W. E., Cloud G. A. Ketoconazole therapy of progressive coccidioidomycosis. Comparison of 400- and 800-mg doses and observations at higher doses. Am J Med. 1988 Mar;84(3 Pt 2):603–610. doi: 10.1016/0002-9343(88)90143-x. [DOI] [PubMed] [Google Scholar]
- Galgiani J. N. Susceptibility testing of fungi: current status of the standardization process. Antimicrob Agents Chemother. 1993 Dec;37(12):2517–2521. doi: 10.1128/aac.37.12.2517. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Ghannoum M. A., Ibrahim A. S., Fu Y., Shafiq M. C., Edwards J. E., Jr, Criddle R. S. Susceptibility testing of Cryptococcus neoformans: a microdilution technique. J Clin Microbiol. 1992 Nov;30(11):2881–2886. doi: 10.1128/jcm.30.11.2881-2886.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Goff D. A., Koletar S. L., Buesching W. J., Barnishan J., Fass R. J. Isolation of fluconazole-resistant Candida albicans from human immunodeficiency virus-negative patients never treated with azoles. Clin Infect Dis. 1995 Jan;20(1):77–83. doi: 10.1093/clinids/20.1.77. [DOI] [PubMed] [Google Scholar]
- Grant S. M., Clissold S. P. Fluconazole. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial and systemic mycoses. Drugs. 1990 Jun;39(6):877–916. doi: 10.2165/00003495-199039060-00006. [DOI] [PubMed] [Google Scholar]
- Guinet R., Nerson D., de Closets F., Dupouy-Camet J., Kures L., Marjollet M., Poirot J. L., Ros A., Texier-Maugein J., Volle P. J. Collaborative evaluation in seven laboratories of a standardized micromethod for yeast susceptibility testing. J Clin Microbiol. 1988 Nov;26(11):2307–2312. doi: 10.1128/jcm.26.11.2307-2312.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
- He X., Tiballi R. N., Zarins L. T., Bradley S. F., Sangeorzan J. A., Kauffman C. A. Azole resistance in oropharyngeal Candida albicans strains isolated from patients infected with human immunodeficiency virus. Antimicrob Agents Chemother. 1994 Oct;38(10):2495–2497. doi: 10.1128/aac.38.10.2495. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Heinic G. S., Stevens D. A., Greenspan D., MacPhail L. A., Dodd C. L., Stringari S., Strull W. M., Hollander H. Fluconazole-resistant Candida in AIDS patients. Report of two cases. Oral Surg Oral Med Oral Pathol. 1993 Dec;76(6):711–715. doi: 10.1016/0030-4220(93)90039-7. [DOI] [PubMed] [Google Scholar]
- Horn C. A., Washburn R. G., Givner L. B., Peacock J. E., Jr, Pegram P. S. Azole-resistant oropharyngeal and esophageal candidiasis in patients with AIDS. AIDS. 1995 May;9(5):533–534. [PubMed] [Google Scholar]
- Horsburgh C. R., Jr, Kirkpatrick C. H. Long-term therapy of chronic mucocutaneous candidiasis with ketoconazole: experience with twenty-one patients. Am J Med. 1983 Jan 24;74(1B):23–29. doi: 10.1016/0002-9343(83)90511-9. [DOI] [PubMed] [Google Scholar]
- Johnson E. M., Richardson M. D., Warnock D. W. In-vitro resistance to imidazole antifungals in Candida albicans. J Antimicrob Chemother. 1984 Jun;13(6):547–558. doi: 10.1093/jac/13.6.547. [DOI] [PubMed] [Google Scholar]
- Kitchen V. S., Savage M., Harris J. R. Candida albicans resistance in AIDS. J Infect. 1991 Mar;22(2):204–205. doi: 10.1016/0163-4453(91)91789-z. [DOI] [PubMed] [Google Scholar]
- Larsen R. A., Bozzette S. A., Jones B. E., Haghighat D., Leal M. A., Forthal D., Bauer M., Tilles J. G., McCutchan J. A., Leedom J. M. Fluconazole combined with flucytosine for treatment of cryptococcal meningitis in patients with AIDS. Clin Infect Dis. 1994 Oct;19(4):741–745. doi: 10.1093/clinids/19.4.741. [DOI] [PubMed] [Google Scholar]
- McIntyre K. A., Galgiani J. N. pH and other effects on the antifungal activity of cilofungin (LY121019). Antimicrob Agents Chemother. 1989 May;33(5):731–735. doi: 10.1128/aac.33.5.731. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Merz W. G. Candida lusitaniae: frequency of recovery, colonization, infection, and amphotericin B resistance. J Clin Microbiol. 1984 Dec;20(6):1194–1195. doi: 10.1128/jcm.20.6.1194-1195.1984. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Millon L., Manteaux A., Reboux G., Drobacheff C., Monod M., Barale T., Michel-Briand Y. Fluconazole-resistant recurrent oral candidiasis in human immunodeficiency virus-positive patients: persistence of Candida albicans strains with the same genotype. J Clin Microbiol. 1994 Apr;32(4):1115–1118. doi: 10.1128/jcm.32.4.1115-1118.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Newman S. L., Flanigan T. P., Fisher A., Rinaldi M. G., Stein M., Vigilante K. Clinically significant mucosal candidiasis resistant to fluconazole treatment in patients with AIDS. Clin Infect Dis. 1994 Oct;19(4):684–686. doi: 10.1093/clinids/19.4.684. [DOI] [PubMed] [Google Scholar]
- Pappagianis D., Collins M. S., Hector R., Remington J. Development of resistance to amphotericin B in Candida lusitaniae infecting a human. Antimicrob Agents Chemother. 1979 Aug;16(2):123–126. doi: 10.1128/aac.16.2.123. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Paugam A., Dupouy-Camet J., Blanche P., Gangneux J. P., Tourte-Schaefer C., Sicard D. Increased fluconazole resistance of Cryptococcus neoformans isolated from a patient with AIDS and recurrent meningitis. Clin Infect Dis. 1994 Nov;19(5):975–976. doi: 10.1093/clinids/19.5.975-a. [DOI] [PubMed] [Google Scholar]
- Pfaller M. A., Bale M., Buschelman B., Lancaster M., Espinel-Ingroff A., Rex J. H., Rinaldi M. G., Cooper C. R., McGinnis M. R. Quality control guidelines for National Committee for Clinical Laboratory Standards recommended broth macrodilution testing of amphotericin B, fluconazole, and flucytosine. J Clin Microbiol. 1995 May;33(5):1104–1107. doi: 10.1128/jcm.33.5.1104-1107.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Pfaller M. A., Barry A. L. Evaluation of a novel colorimetric broth microdilution method for antifungal susceptibility testing of yeast isolates. J Clin Microbiol. 1994 Aug;32(8):1992–1996. doi: 10.1128/jcm.32.8.1992-1996.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Pfaller M. A., Burmeister L., Bartlett M. S., Rinaldi M. G. Multicenter evaluation of four methods of yeast inoculum preparation. J Clin Microbiol. 1988 Aug;26(8):1437–1441. doi: 10.1128/jcm.26.8.1437-1441.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Pfaller M. A., Rhine-Chalberg J., Redding S. W., Smith J., Farinacci G., Fothergill A. W., Rinaldi M. G. Variations in fluconazole susceptibility and electrophoretic karyotype among oral isolates of Candida albicans from patients with AIDS and oral candidiasis. J Clin Microbiol. 1994 Jan;32(1):59–64. doi: 10.1128/jcm.32.1.59-64.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Pfaller M. A., Rinaldi M. G., Galgiani J. N., Bartlett M. S., Body B. A., Espinel-Ingroff A., Fromtling R. A., Hall G. S., Hughes C. E., Odds F. C. Collaborative investigation of variables in susceptibility testing of yeasts. Antimicrob Agents Chemother. 1990 Sep;34(9):1648–1654. doi: 10.1128/aac.34.9.1648. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Polak A. Multicenter-Studie zur Standardisierung der Empfindlichkeitsbestimmung von Pilzen gegen 5-Fluorcytosin und Amphotericin B. Mykosen. 1987 Jul;30(7):306-8, 311-4. [PubMed] [Google Scholar]
- Powderly W. G., Kobayashi G. S., Herzig G. P., Medoff G. Amphotericin B-resistant yeast infection in severely immunocompromised patients. Am J Med. 1988 May;84(5):826–832. doi: 10.1016/0002-9343(88)90059-9. [DOI] [PubMed] [Google Scholar]
- Radetsky M., Wheeler R. C., Roe M. H., Todd J. K. Microtiter broth dilution method for yeast susceptibility testing with validation by clinical outcome. J Clin Microbiol. 1986 Oct;24(4):600–606. doi: 10.1128/jcm.24.4.600-606.1986. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Redding S., Smith J., Farinacci G., Rinaldi M., Fothergill A., Rhine-Chalberg J., Pfaller M. Resistance of Candida albicans to fluconazole during treatment of oropharyngeal candidiasis in a patient with AIDS: documentation by in vitro susceptibility testing and DNA subtype analysis. Clin Infect Dis. 1994 Feb;18(2):240–242. doi: 10.1093/clinids/18.2.240. [DOI] [PubMed] [Google Scholar]
- Rex J. H., Bennett J. E., Sugar A. M., Pappas P. G., van der Horst C. M., Edwards J. E., Washburn R. G., Scheld W. M., Karchmer A. W., Dine A. P. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia Study Group and the National Institute. N Engl J Med. 1994 Nov 17;331(20):1325–1330. doi: 10.1056/NEJM199411173312001. [DOI] [PubMed] [Google Scholar]
- Rex J. H., Cooper C. R., Jr, Merz W. G., Galgiani J. N., Anaissie E. J. Detection of amphotericin B-resistant Candida isolates in a broth-based system. Antimicrob Agents Chemother. 1995 Apr;39(4):906–909. doi: 10.1128/aac.39.4.906. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Rex J. H., Pfaller M. A., Barry A. L., Nelson P. W., Webb C. D. Antifungal susceptibility testing of isolates from a randomized, multicenter trial of fluconazole versus amphotericin B as treatment of nonneutropenic patients with candidemia. NIAID Mycoses Study Group and the Candidemia Study Group. Antimicrob Agents Chemother. 1995 Jan;39(1):40–44. doi: 10.1128/aac.39.1.40. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Rex J. H., Pfaller M. A., Rinaldi M. G., Polak A., Galgiani J. N. Antifungal susceptibility testing. Clin Microbiol Rev. 1993 Oct;6(4):367–381. doi: 10.1128/cmr.6.4.367. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Rex J. H., Rinaldi M. G., Pfaller M. A. Resistance of Candida species to fluconazole. Antimicrob Agents Chemother. 1995 Jan;39(1):1–8. doi: 10.1128/aac.39.1.1. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Reynes J., Mallié M., André D., Janbon F., Bastide J. M. Traitement et prophylaxie secondaire par fluconazole des candidoses oropharyngées des sujets VIH +. Analyse mycologique des echecs. Pathol Biol (Paris) 1992 May;40(5):513–517. [PubMed] [Google Scholar]
- Ruhnke M., Eigler A., Engelmann E., Geiseler B., Trautmann M. Correlation between antifungal susceptibility testing of Candida isolates from patients with HIV infection and clinical results after treatment with fluconazole. Infection. 1994 Mar-Apr;22(2):132–136. doi: 10.1007/BF01739024. [DOI] [PubMed] [Google Scholar]
- Ruhnke M., Eigler A., Tennagen I., Geiseler B., Engelmann E., Trautmann M. Emergence of fluconazole-resistant strains of Candida albicans in patients with recurrent oropharyngeal candidosis and human immunodeficiency virus infection. J Clin Microbiol. 1994 Sep;32(9):2092–2098. doi: 10.1128/jcm.32.9.2092-2098.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Sanders C. C. ARTs versus ASTs: where are we going? J Antimicrob Chemother. 1991 Nov;28(5):621–623. doi: 10.1093/jac/28.5.621. [DOI] [PubMed] [Google Scholar]
- Sandven P., Bjørneklett A., Maeland A. Susceptibilities of Norwegian Candida albicans strains to fluconazole: emergence of resistance. The Norwegian Yeast Study Group. Antimicrob Agents Chemother. 1993 Nov;37(11):2443–2448. doi: 10.1128/aac.37.11.2443. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Sangeorzan J. A., Bradley S. F., He X., Zarins L. T., Ridenour G. L., Tiballi R. N., Kauffman C. A. Epidemiology of oral candidiasis in HIV-infected patients: colonization, infection, treatment, and emergence of fluconazole resistance. Am J Med. 1994 Oct;97(4):339–346. doi: 10.1016/0002-9343(94)90300-x. [DOI] [PubMed] [Google Scholar]
- Sanguineti A., Carmichael J. K., Campbell K. Fluconazole-resistant Candida albicans after long-term suppressive therapy. Arch Intern Med. 1993 May 10;153(9):1122–1124. [PubMed] [Google Scholar]
- Shadomy S., White S. C., Yu H. P., Dismukes W. E. Treatment of systemic mycoses with ketoconazole: in vitro susceptibilities of clinical isolates of systemic and pathogenic fungi to ketoconazole. J Infect Dis. 1985 Dec;152(6):1249–1256. doi: 10.1093/infdis/152.6.1249. [DOI] [PubMed] [Google Scholar]
- Shawar R., Paetznick V., Witte Z., Ensign L. G., Anaissie E., LaRocco M. Collaborative investigation of broth microdilution and semisolid agar dilution for in vitro susceptibility testing of Candida albicans. J Clin Microbiol. 1992 Aug;30(8):1976–1981. doi: 10.1128/jcm.30.8.1976-1981.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Smith D., Boag F., Midgley J., Gazzard B. Fluconazole resistant candida in AIDS. J Infect. 1991 Nov;23(3):345–346. doi: 10.1016/0163-4453(91)93584-y. [DOI] [PubMed] [Google Scholar]
- Smith K. J., Warnock D. W., Kennedy C. T., Johnson E. M., Hopwood V., Van Cutsem J., Vanden Bossche H. Azole resistance in Candida albicans. J Med Vet Mycol. 1986 Apr;24(2):133–144. [PubMed] [Google Scholar]
- Stiller R. L., Bennett J. E., Scholer H. J., Wall M., Polak A., Stevens D. A. Susceptibility to 5-fluorocytosine and prevalence of serotype in 402 Candida albicans isolates from the United States. Antimicrob Agents Chemother. 1982 Sep;22(3):482–487. doi: 10.1128/aac.22.3.482. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Tiballi R. N., He X., Zarins L. T., Revankar S. G., Kauffman C. A. Use of a colorimetric system for yeast susceptibility testing. J Clin Microbiol. 1995 Apr;33(4):915–917. doi: 10.1128/jcm.33.4.915-917.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Troillet N., Durussel C., Bille J., Glauser M. P., Chave J. P. Correlation between in vitro susceptibility of Candida albicans and fluconazole-resistant oropharyngeal candidiasis in HIV-infected patients. Eur J Clin Microbiol Infect Dis. 1993 Dec;12(12):911–915. doi: 10.1007/BF01992164. [DOI] [PubMed] [Google Scholar]
- Velez J. D., Allendoerfer R., Luther M., Rinaldi M. G., Graybill J. R. Correlation of in vitro azole susceptibility with in vivo response in a murine model of cryptococcal meningitis. J Infect Dis. 1993 Aug;168(2):508–510. doi: 10.1093/infdis/168.2.508. [DOI] [PubMed] [Google Scholar]
- Vuffray A., Durussel C., Boerlin P., Boerlin-Petzold F., Bille J., Glauser M. P., Chave J. P. Oropharyngeal candidiasis resistant to single-dose therapy with fluconazole in HIV-infected patients. AIDS. 1994 May;8(5):708–709. doi: 10.1097/00002030-199405000-00023. [DOI] [PubMed] [Google Scholar]
- Walsh T. J., Melcher G. P., Rinaldi M. G., Lecciones J., McGough D. A., Kelly P., Lee J., Callender D., Rubin M., Pizzo P. A. Trichosporon beigelii, an emerging pathogen resistant to amphotericin B. J Clin Microbiol. 1990 Jul;28(7):1616–1622. doi: 10.1128/jcm.28.7.1616-1622.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Warnock D. W., Burke J., Cope N. J., Johnson E. M., von Fraunhofer N. A., Williams E. W. Fluconazole resistance in Candida glabrata. Lancet. 1988 Dec 3;2(8623):1310–1310. doi: 10.1016/s0140-6736(88)92919-4. [DOI] [PubMed] [Google Scholar]
- White A., Goetz M. B. Azole-resistant Candida albicans: report of two cases of resistance to fluconazole and review. Clin Infect Dis. 1994 Oct;19(4):687–692. doi: 10.1093/clinids/19.4.687. [DOI] [PubMed] [Google Scholar]
- Willocks L., Leen C. L., Brettle R. P., Urquhart D., Russell T. B., Milne L. J. Fluconazole resistance in AIDS patients. J Antimicrob Chemother. 1991 Dec;28(6):937–939. doi: 10.1093/jac/28.6.937. [DOI] [PubMed] [Google Scholar]
- Wingard J. R., Merz W. G., Rinaldi M. G., Johnson T. R., Karp J. E., Saral R. Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole. N Engl J Med. 1991 Oct 31;325(18):1274–1277. doi: 10.1056/NEJM199110313251803. [DOI] [PubMed] [Google Scholar]